DCC-3014, Vimseltinib (Deciphera) is the name of a medication currently in trial for TGCT.
It is a Phase II/III study, meaning the side effects are being evaluated as well as the effectiveness of the drug. The Phase III trial is known as MOTION.
Preliminary data shows it has an improved tolerability profile and remains effective at shrinking TGCT.
It is currently recruiting at 18 different global clinical locations. Vimseltinib or a sugar drug (placebo) is given twice weekly for 24 weeks. Following 24 weeks, Vimseltinib is given to all participants. At any time, patients given the sugar pill can cross over into the Vimseltinib group. The objective of this trial is to review tumor shrinkage at 25 weeks, range of motion, and patient reported pain, stiffness, and function.
